Business Brief -- Genzyme Corp.:
   Cystic Fibrosis Drug Gets
   Orphan-Drug Designation
Cystic fibrosis, which affects about 30,000 people in the
U.S., is a fatal inherited disorder that clogs the airways
with thick mucous and causes respiratory and digestive
problems.
   Orphan-drug status qualifies the owner of its patent for
exclusive marketing rights for seven years, subject to FDA
approval of the owner's new drug application. Genzyme is
developing r-CFTR with Neozyme Corp., a research and
development company that Genzyme formed in 1989.